

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 03 May 2022.

I am pleased to confirm the following.

Q1. How many patients has your trust treated in the past 3 months for the following conditions:

- **Chronic Lymphocytic Leukaemia (CLL) TOTAL 34**
- **Mantle Cell Lymphoma (MCL) TOTAL 5**
- **In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.**

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab) TOTAL 1**
- **Calquence (acalabrutinib) TOTAL 12**
- **FCR (fludarabine + cyclophosphamide + rituximab) TOTAL 0**
- **Gazyva (obinutuzumab) + chlorambucil TOTAL 0**
- **Imbruvica (ibrutinib) TOTAL 17**
- **Venclexta (venetoclax) TOTAL 0**
- **Venclexta (venetoclax) + Gazyva (obinutuzumab) TOTAL 0**
- **Venclexta (venetoclax) + rituximab TOTAL 0**
- **Zydelig (idelalisib) + rituximab TOTAL 0**
- **Any other systemic anti-cancer therapy TOTAL 4**

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab) TOTAL 0**
- **Imbruvica (ibrutinib) TOTAL 0**
- **Imbruvica (ibrutinib) + rituximab TOTAL 3**
- **R-BAC (rituximab, bendamustine and cytarabine) TOTAL 0**
- **R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) TOTAL 1**
- **Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone) TOTAL 1**

- **Velcade (bortezomib) + chemotherapy** TOTAL 0
- **Any other systemic anti-cancer therapy** TOTAL 0
- **Stem cell transplant** TOTAL 0
- **Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells** TOTAL 0

Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Open to recruitment

LOXO -BTK 200020: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) – none recruited so far

Closed to recruitment but in follow up

NCRN210 – FLAIR: Front line therapy in CLL: Assessment of Ibrutinib and Rituximab
19 patients recruited

RIAltO: A Randomised Investigation of Alternative Ofatumumab[1]containing regimens in less fit patients with CLL

1 patient recruited

Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part

Closed to recruitment but in follow up

ENRICH: Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma
2 patients recruited

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator

For and on behalf of Milton Keynes Hospital NHS Foundation Trust

<p>Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.</p>
